BERKELEY LIGHTS INC (BLI)

US0843101017 - Common Stock

1.2  -0.07 (-5.88%)

After market: 1.21 +0.01 (+0.83%)

Fundamental Rating

2

BLI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BLI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BLI is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

BLI had negative earnings in the past year.
BLI had a negative operating cash flow in the past year.
In the past 5 years BLI always reported negative net income.
In the past 5 years BLI always reported negative operating cash flow.

1.2 Ratios

BLI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 68.43%, BLI belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
In the last couple of years the Gross Margin of BLI has declined.
The Profit Margin and Operating Margin are not available for BLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

BLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLI has more shares outstanding
BLI has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.23, we must say that BLI is in the distress zone and has some risk of bankruptcy.
BLI's Altman-Z score of -2.23 is on the low side compared to the rest of the industry. BLI is outperformed by 81.25% of its industry peers.
BLI has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BLI has a Debt to Equity ratio of 0.10. This is comparable to the rest of the industry: BLI outperforms 56.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -2.23
ROIC/WACCN/A
WACC8.97%

2.3 Liquidity

BLI has a Current Ratio of 3.89. This indicates that BLI is financially healthy and has no problem in meeting its short term obligations.
BLI has a Current ratio (3.89) which is comparable to the rest of the industry.
A Quick Ratio of 3.48 indicates that BLI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.48, BLI is in line with its industry, outperforming 51.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.48

4

3. Growth

3.1 Past

BLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.64%.
The Revenue has decreased by -7.96% in the past year.
BLI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.51% yearly.
EPS 1Y (TTM)-33.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-57.69%
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Revenue growth Q2Q-23.05%

3.2 Future

The Earnings Per Share is expected to grow by 19.00% on average over the next years. This is quite good.
BLI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.80% yearly.
EPS Next Y24.43%
EPS Next 2Y15.53%
EPS Next 3Y19%
EPS Next 5YN/A
Revenue Next Year11.33%
Revenue Next 2Y15.66%
Revenue Next 3Y17.8%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BLI's earnings are expected to grow with 19.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.53%
EPS Next 3Y19%

0

5. Dividend

5.1 Amount

No dividends for BLI!.
Industry RankSector Rank
Dividend Yield N/A

BERKELEY LIGHTS INC

NASDAQ:BLI (3/21/2023, 8:00:01 PM)

After market: 1.21 +0.01 (+0.83%)

1.2

-0.07 (-5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap47.72M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 68.43%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.89
Quick Ratio 3.48
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y24.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y11.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y